Credit Suisse Maintains Neutral on GoodRx Holdings, Raises Price Target to $8
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Jonathan Yong has maintained a Neutral rating on GoodRx Holdings (NASDAQ:GDRX) and raised the price target from $7 to $8.

August 10, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Credit Suisse has maintained a Neutral rating on GoodRx Holdings and raised the price target from $7 to $8.
The news is directly about GoodRx Holdings. The Neutral rating indicates that the analyst does not expect significant price movement in the short term. However, the increase in price target could be seen as a positive signal, but it's not strong enough to predict a price increase.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100